June 22, 2017: Here are four stocks trading with heavy volume among 106 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by nearly 3 to 2 and on the Nasdaq, advancers led decliners by about the same ratio.
The Hain Celestial Group Inc. (NASDAQ: HAIN) posted a new 52-week low of $31.70 on Thursday, down about 4.4% compared with Wednesday’s closing price of $33.16. The stock’s 52-week high is $56.99. Volume totaled more than 12.5 million shares, about 10 times the daily average of around 1.2 million. The organic food company said this morning that an accounting review has shown that the company does not need to change its accounting practices. Shares turned positive later in the day and are on track to close up about 1%.
DDR Corp. (NYSE: DDR) dropped about 3.2% Thursday to post a new 52-week low of $8.11 after closing at $8.38 on Wednesday. The stock’s 52-week high is $19.92. Volume of nearly 12 million was about 40% higher than the daily average. The company had no specific news.
financial markets: The Michaels Companies, Inc.(MIK)
Advisors’ Opinion:
- [By Laurie Kulikowski]
We rate MICHAELS COS INC as a Sell with a ratings score of D+. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been weak operating cash flow.
- [By Jim Cramer]
After a year of stock price fluctuations, the net result is that MIK’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. Turning toward the future, the fact that the stock has come down in price over the past year should not necessarily be interpreted as a negative; it could be one of the factors that may help make the stock attractive down the road. Right now, however, we believe that it is too soon to buy.
- [By Jim Cramer]
The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Specialty Retail industry average. The net income increased by 20.0% when compared to the same quarter one year prior, going from $64.00 million to $76.80 million.
- [By WWW.THESTREET.COM]
Earnings of note in the coming week include Analogic (ALOG) and Ascena Retail (ASNA) on Monday; Bojangles (BOJA) , H&R Block (HRB) , and Dick’s Sporting Goods (DKS) , Michaels (MIK) , and Urban Outfitters (URBN) on Tuesday; Ciena (CIEN) , Bankrate (RATE) , Express (EXPR) , Vera Bradley (VRA) , and Bob Evans Farms (BOBE) on Wednesday; El Pollo Loco (LOCO) , Hugo Boss (BOSSY) , Party City (PRTY) , Signet Jewelers (SIG) , and Verifone Systems (PAY) on Thursday; and Kirkland’s (KIRK) , and Vail Resorts (MTN) on Friday.
- [By JPMorgan]
MIK’s results over the past year point to the company’s success in improving merchandising, marketing, and in-store execution plus the benefits of having a functioning e-commerce website. We believe part of the challenge for the bears is both a lack of appreciation for the category as well as missing the historical context of how leadership has evolved. Indeed, the difference in focus on "the front end" under CEO Chuck Rubin (who arrived in 2013) vs. a more process-oriented and margin-focused CEO prior to his arrival left a lot of impactful, low hanging fruit opportunities. Finally, while we acknowledge that longer term the sustainable comp is lower than the recent ~4% underlying trend, we point to the low volatility of sales, high cash generative nature of the business, barriers to entry (e.g., high SKU density, low inventory turns, lack of brands), and MIK’s market leadership as reasons why the multiple has the potential to expand over time (a la AZO). Balance sheet de-levering should also make the PE look increasingly cheap over time and transfer cash/value to equity holders.
- [By Jim Cramer]
42.37% is the gross profit margin for MICHAELS COS INC which we consider to be strong. Regardless of MIK’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 6.57% trails the industry average.
MICHAELS COS INC has improved earnings per share by 19.4% in the most recent quarter compared to the same quarter a year ago. This year, the market expects an improvement in earnings ($1.70 versus $1.04).
financial markets: Sage Therapeutics, Inc.(SAGE)
Advisors’ Opinion:
- [By Lisa Levin]
SAGE Therapeutics Inc (NASDAQ: SAGE) shares shot up 73 percent to $159.39 after the company disclosed that Phase 2 trial of SAGE-217 met its primary endpoint.
- [By WWW.THESTREET.COM]
Position: Long GLD small, bonds, SDS; short TLT small, SPY small .
- [By Chris Lange]
Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) saw an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial. Specifically, the firm reported results from its Phase 2 trial of Sage-217 for the treatment of moderate to severe major depressive disorder (MDD).
- [By WWW.THESTREET.COM]
The Good
The market remains resistant (Rs over Ss and Ns). Brokerages, banks and insurance companies continue their league-leading strength. The Russell 2000 Index is up for the 15th consecutive day. Retail extends yesterday’s strength. Nordstrom (JWN) , Macy’s (M) , Best Buy (BBY) , Target (TGT) , Walmart (WMT) , Foot Locker (FL) and JCPenney (JCP) are strong. First day down for Amazon (AMZN) . Agricultural commodities are lackluster, but soybeans are up another up $0.05 today, up substantially for three days in a row. Speculative biotech (Sage (SAGE) , FibroGen (FGEN) , Acadia Pharmaceuticals (ACAD) and Aerie Pharmaceuticals (AERI) ) stronger after recent weakness. Ag equipment up big time after the Deere (DE) beat.
The Bad
financial markets: WildHorse Resource Development Corporation (WRD)
Advisors’ Opinion:
- [By Paul Ausick]
WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.
financial markets: VEXIM EUR0.10 (VXMFF)
Advisors’ Opinion:
- [By SEEKINGALPHA.COM]
French medical device maker Vexim (OTC:VXMFF) contracted with an unnamed China lab to begin China registration studies for its vertebral fracture repair device, SpineJack庐. Vexim recently was granted patents for the device in China and Japan. SpineJack is an implant designed to repair a fractured vertebra and restore spinal cord balance. The 30 minute procedure is useful in 95% of vertebral fractures, according to Vexim. SpineJack was CE marked for EU use in 2010 and now is indicated for trauma and other vertebral fractures.
financial markets: Xcel Energy Inc.(XEL)
Advisors’ Opinion:
- [By Shauna O’Brien]
Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).
The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.
Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”
“Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.
Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.
Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.
financial markets: Chiasma, Inc.(CHMA)
Advisors’ Opinion:
- [By Lisa Levin]
Chiasma Inc (NASDAQ: CHMA) was down, falling around 13 percent to $9.51 ahead of the U.S. Food and Drug Administration’s decision on Friday to approve or reject the company’s therapy. The status of its oral treatment for acromegaly, a capsule known as Mycapssa, will be in focus on Friday. The Street’s biotechnology expert Adam Feuerstein stated that an investor source believes the FDA will reject Chiasma’s capsules because data from a single-arm study failed to demonstrate a clinically meaningful benefit among patients.
